Raymond James upgraded Doximity Inc (DOCS) to Strong Buy from Outperform on November 20, 2025. The stock is currently priced at $49.95.
This upgrade reflects a more optimistic outlook on Doximity's prospects, potentially signaling improved fundamentals or better-than-expected business performance. The company, which operates an online platform for medical professionals, has a market capitalization of $10.2 billion and a P/E ratio of 43.25. Doximity reported Q2 2026 earnings of $0.45 per share, exceeding estimates by 16.4%.
Upcoming earnings reports are scheduled for May 13, 2026, with an estimated EPS of $0.33 and revenue of $153.3 million, and August 5, 2026, with an estimated EPS of $0.37 and revenue of $165.6 million.
Analyst consensus currently rates Doximity as a Buy, with 8 Strong Buy, 8 Buy, 8 Hold, and 2 Sell ratings. Analyst ratings can shift as new information emerges, so they should be considered alongside other factors when making investment decisions.